Proimmune — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ProImmune is a private, revenue-generating company headquartered in Oxford, UK, operating as a hybrid platform and services business in the immunology and diagnostics sectors. Its core technology is the Ankyron® platform, which produces small, high-specificity recombinant monoclonal binding reagents, complemented by a broad portfolio of MHC-related reagents and immunology testing services. The company serves a global clientele in pharmaceutical development and academic research, leveraging strategic collaborations, such as with the Roslin Institute, to expand into veterinary immunology and strengthen its market position. ProImmune also fosters industry engagement through events like its 'Mastering Immunity' symposium series.

ImmunologyInfectious DiseasesOncology (implied by immunology tools)

Technology Platform

Proprietary Ankyron® platform for generating small (~15 kDa), high-specificity recombinant monoclonal binding proteins (binders) as alternatives to antibodies; plus deep expertise and product lines in MHC (Major Histocompatibility Complex) reagents including tetramers, pentamers, and monomers for T-cell research.

Opportunities

Significant opportunity in displacing traditional research antibodies with superior, reproducible Ankyron binders across multiple species.

The underserved veterinary immunology market and the growing need for immunogenicity testing in biotherapeutic development represent substantial greenfield and expansion areas.

Strategic entry into the Asia-Pacific biopharma market, particularly China, offers a major growth vector.

Risk Factors

Faces intense competition from large, established life science tools companies and other startups in the recombinant binder and MHC reagent space.

Revenue is susceptible to fluctuations in global R&D spending across academia and biotech.

Successful scaling of custom reagent production and international operations, especially in China, presents execution challenges.

Competitive Landscape

ProImmune competes in the crowded life science reagents and services market against giants like Thermo Fisher Scientific, BioLegend, and Sino Biological, as well as specialized players in MHC reagents (e.g., ImmunoSeq, MBL International). Its differentiation hinges on the Ankyron technology's claimed advantages (size, specificity, cost) and its integrated service portfolio for immunogenicity. In veterinary immunology, it faces less competition but must drive market creation.

More companies in Immunotherapy / Immuno-Oncology →More companies in United Kingdom →